Advertisement

Electronic Monitoring of Medication Adherence: From Dose-Counting to Dose-Clocking

  • Bernard Vrijens
  • Eric Tousset
Chapter
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)

Abstract

Poor adherence to prescribed dosing regimens is one of the greatest sources of variation in drug response, often leading to underestimates of drug efficacy and side effects, and doses set needlessly high. The use of electronic monitors provides a continuous, compiled in real time, record of patient dosing times, dates, and patterns. Knowing the when of patient dosing activity allows one to accurately gauge drug efficacy and build reliable prognostics and claims. Objective dosing history data supports faster, smarter clinical drug development and avoids wasting time and money in medical practice. Failure to monitor individual dosing patterns means discounting the impact of poor adherence—the factor that is emerging as the single greatest cause of failed drug therapy.

Keywords

Medication adherence MEMS Electronic monitoring Rich data 

References

  1. 1.
    Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Dobbels F, De Geest S, van Cleemput J, Droogne W, Vanhaecke J. Effect of late medication non-compliance on outcome after heart transplantation: a 5-year follow-up. J Heart Lung Transplant. 2004;23(11):1245–51.CrossRefPubMedGoogle Scholar
  3. 3.
    Bhatia S, Landier W, Hageman L, Chen Y, Kim H, Sun CL, Kornegay N, Evans WE, Angiolillo AL, Bostrom B, Casillas J, Lew G, Maloney KW, Mascarenhas L, Ritchey AK, Termuhlen AM, Carroll WL, Wong FL, Relling MV. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a Children’s Oncology Group Study. JAMA Oncol. 2015;1(3):287–95.  https://doi.org/10.1001/jamaoncol.2015.0245.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52:275–301.CrossRefPubMedGoogle Scholar
  5. 5.
    Vrijens B, Urquhart J. Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. Clin Pharmacol Ther. 2014;95(6):617–26.  https://doi.org/10.1038/clpt.2014.59. Epub 2014 Mar 12.CrossRefPubMedGoogle Scholar
  6. 6.
    Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J, ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P, De Geest S, Dobbels F, Lewek P, Urquhart J, Vrijens B, ABC Project Team. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs. 2013;73(6):545–62.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Burnier M, Schneider MP, Chioléro A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens. 2001;19(2):335–41.CrossRefPubMedGoogle Scholar
  9. 9.
    Vrijens B, Urquhart J, White D. Electronically monitored dosing histories can be used to develop a medication-taking habit and manage patient adherence. Expert Rev Clin Pharmacol. 2014;7(5):633–44.CrossRefPubMedGoogle Scholar
  10. 10.
    Volpp KG, Troxel AB, Mehta SJ, Norton L, Zhu J, Lim R, Wang W, Marcus N, Terwiesch C, Caldarella K, Levin T, Relish M, Negin N, Smith-McLallen A, Snyder R, Spettell CM, Drachman B, Kolansky D, Asch DA. Effect of electronic reminders, financial incentives, and social support on outcomes after myocardial infarction: the HeartStrong randomized clinical trial. JAMA Intern Med. 2017;177(8):1093–101.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Advanced Analytical Research on Drug EXposure (AARDEX Group)ViséBelgium
  2. 2.Department of Public HealthUniversity of LiègeLiègeBelgium

Personalised recommendations